Key result
Treatment with 20 μM Atractylodin prevented calcified nodule accumulation and ameliorated aortic valve calcification by targeting GLA to regulate D-mannose metabolism.
Why the study?
Inflammation-induced osteogenic changes in valve interstitial cells drive calcified aortic valve disease, but the anti-calcification effects of atractylodin remained to be investigated.
Does Atractylodin inhibit osteogenic differentiation and ameliorate aortic valve calcification in preclinical models?
Does Atractylodin inhibit osteogenic differentiation and ameliorate aortic valve calcification in preclinical models?
Atractylodin demonstrates potential as a therapeutic agent for calcified aortic valve disease by targeting GLA to regulate D-mannose metabolism and inhibit inflammation-induced osteogenic differentiation.
No takes yet. Share an insight, caveat, or question.
Atractylodin may target GLA in aortic valve calcification; hypothesis-generating and requires clinical validation.
Qu et al. (2022) studied Calcified aortic valve disease. Atractylodin vs. Control (osteogenic induction medium or high-fat diet) was evaluated on Osteogenic differentiation and aortic valve calcification. Treatment with 20 μM Atractylodin prevented calcified nodule accumulation and ameliorated aortic valve calcification by targeting GLA to regulate D-mannose metabolism.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: